Hikma Pharmaceuticals (H5P) Price & Analysis
H5P Stock Chart & Stats
- Day’s Range
- EUR 20.42 - EUR 20.52
- 52-Week Range
- EUR 13.80 - EUR 21.20
- Previous Close
- EUR 20.60
- Volume
- 0
- Average Volume (3M)
- 212
- Market Cap
- EUR 4.28B
- Enterprise Value
- EUR 4.59B
- Total Cash (Recent Filing)
- EUR 290.50M
- Total Debt (Recent Filing)
- EUR 1.97B
- Price to Earnings (P/E)
- 12.9
- Beta
- 0.54
- Next Earnings
- Feb 25, 2027
- EPS Estimate
- 0.98
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 3.61%
Bulls Say, Bears Say
Bulls Say
Steady Revenue Growth And Earnings Recovery
Hikma has maintained a solid top-line trajectory while restoring earnings after the 2022–2023 dip. This indicates improved execution across its portfolio and provides a stronger base for continued investment, product launches and operating resilience over the next several quarters.
Injectables Operations Stabilized
Injectables can provide differentiation beyond highly commoditized generic medicines when manufacturing reliability and complex product capabilities are strong. The reported operational improvements and expanding submission cadence support better supply execution and a broader medium-term growth pipeline.
Strong MENA Market Position
Leadership in MENA oncology and gains across several major markets demonstrate established regional commercial capabilities and brand strength. Continued launches and share gains can support diversified growth, reducing reliance on any single geographic market or product category.
Bears Say
Sharp Deterioration In Cash Generation
The steep decline in operating and free cash flow, together with free cash flow at about 45% of net income, signals weaker cash conversion than reported profitability. If persistent, this could constrain internally funded investment and reduce flexibility for capital allocation.
Higher Leverage And Compressed Margins
Hikma remains reasonably sound, but rising leverage reduces financial flexibility compared with prior years, while lower gross margins show profitability has become less protected. Together, these trends could make the business more sensitive to competition, investment needs and operational setbacks.
Generic Price Erosion And Competition
Ongoing price erosion and competition in oral generics can reduce the economic value of established products even when volumes remain stable. Pressure in categories such as Advair may weigh on Rx margins and require continued launches, cost control and portfolio renewal.
Hikma Pharmaceuticals News
H5P FAQ
What was Hikma Pharmaceuticals’s price range in the past 12 months?
What is Hikma Pharmaceuticals’s market cap?
When is Hikma Pharmaceuticals’s upcoming earnings report date?
How were Hikma Pharmaceuticals’s earnings last quarter?
Is Hikma Pharmaceuticals overvalued?
Does Hikma Pharmaceuticals pay dividends?
What is Hikma Pharmaceuticals’s EPS estimate?
How many shares outstanding does Hikma Pharmaceuticals have?
What happened to Hikma Pharmaceuticals’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Hikma Pharmaceuticals?
What is the TipRanks Smart Score and how is it calculated?
Hikma Pharmaceuticals Stock Smart Score
Company Description
Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC is a global pharmaceutical enterprise involved in the creation, production, promotion, and distribution of a wide array of generic, branded, and licensed medicinal solutions. These offerings are presented in various dosage formats, including solid, semi-solid, liquid, and injectable forms. The company's operations are strategically structured into three core segments: Injectables, Generics, and Branded. The Injectables division specializes in providing generic injectable medications, predominantly for hospital environments. Conversely, the Generics segment is responsible for supplying oral and other non-injectable generic pharmaceuticals to the consumer retail market. The Branded unit caters to both retail and hospital clients with its proprietary generic and in-licensed products. Hikma's comprehensive product portfolio addresses a broad spectrum of medical conditions, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory ailments. The firm boasts a substantial international presence, conducting business across the United Kingdom, the United States, the Middle East, North Africa, and various European countries. Founded in 1978, the company's corporate headquarters are situated in London, United Kingdom.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Said Samih Taleb Darwazah
- Employees
- 9,500
- Website
- www.hikma.com
- Address
- 10 Portman Square, London, GL, W1H 6AZ, GB
Hikma Pharmaceuticals (H5P) Earnings & Revenues
H5P Earnings Call
Earnings Call SentimentNeutral
The call conveyed balanced progress: strong H1 operational and financial performance (EBIT/EBITDA up ~8%, EPS up ~5%), clear operational fixes in injectables, solid MENA momentum, advancing product launches (TYZAVAN, tapentadol) and CMO pipeline, and near‑term proof of capital return via buybacks. Offsetting this are meaningful H2 risks (historical H1 tender weighting and stockpiling normalisation), ongoing price erosion in parts of Rx, divestment of a loss‑making 503B unit, and elevated H2 investment that will temper near‑term margins. Management reiterated full‑year guidance and emphasised continued investment for medium‑term growth (CMO, R&D, US capacity). Overall the positives are meaningful but matched by tangible short‑term headwinds and execution/market risks.
View all DE:H5P earnings summariesH5P Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 13 | 3 | 6 |
| Technical Analysis | 2 | 3 | 5 |
| Moving Averages | 11 | 0 | 1 |